Taken together, PRADX is a novel mesenchymal GBM biomarker, and RUNX1-CBFβ/PRADX/BLCAP/STAT3 axis is the key carcinogenic pathway in mesenchymal GBM, targeting ACSL1 and CPT1 to reduce cellular metabolism might be a potential strategy to treat GBM patients. This evidence concerns the gene RUNX1 and glioblastoma.